A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard Cybord Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma

被引：1
|
作者：
Kotb, Rami [1 ]
Gul, Engin [2 ]
Reece, Donna E. [3 ,4 ]
机构：
[1] Canc Care Manitoba, Winnipeg, MB, Canada
[2] Canadian Myeloma Res Grp, Toronto, ON, Canada
[3] Canadian Myeloma Res Grp Formerly MCRN, Toronto, ON, Canada
[4] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-15363
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4767
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
    O'Donnell, Elizabeth K.
    Mo, Clifton C.
    Yee, Andrew J.
    Nadeem, Omar
    Branagan, Andrew R.
    Laubach, Jacob P.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette
    Harrington, Cynthia C.
    Agyemang, Emerentia
    Spillane, Kerry
    LaStofka, Brenton
    Rosenblatt, Jacalyn
    Raje, Noopur S.
    Richardson, Paul G.
    BLOOD, 2021, 138
  • [2] A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
    O'Donnell, Elizabeth K.
    Mo, Clifton C.
    Nadeem, Omar
    Yee, Andrew J.
    Branagan, Andrew R.
    Laubach, Jacob
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette
    Harrington, Cynthia C.
    Agyemang, Emerentia
    Rosenblatt, Jacalyn
    Horick, Nora K.
    Richardson, Paul G.
    Raje, Noopur
    BLOOD, 2022, 140 : 7282 - 7283
  • [3] A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
    O'Donnell, Elizabeth K.
    Mo, Clifton C.
    Yee, Andrew J.
    Nadeem, Omar
    Branagan, Andrew R.
    Laubach, Jacob
    Rosenblatt, Jacalyn
    Horick, Nora
    Richardson, Paul G.
    Raje, Noopur
    Cirstea, Diana
    BLOOD, 2023, 142
  • [4] IFM guidelines on induction and maintenance for patients with newly diagnosed transplant eligible multiple myeloma
    Macro, Margaret
    HEMATOLOGIE, 2019, 25 (01): : 30 - 40
  • [5] A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment
    Terpos, Evangelos
    Kastritis, Efstathios
    Symeonidis, Argiris
    Pouli, Anastasia
    Delimpasi, Sosana
    Katodritou, Eirini
    Hatzimichael, Eleftheria
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Theodorakakou, Foteini
    Spiliopoulou, Vasiliki
    Syrigou, Rodanthi
    Eleutherakis-Papaiakovou, Evangelos
    Manousou, Kyriaki
    Gavriatopoulou, Maria
    Dimopoulos, Meletios A.
    BLOOD, 2023, 142
  • [6] Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
    Goldschmidt, Hartmut
    Mai, Elias K.
    Nievergall, Eva
    Fenk, Roland
    Bertsch, Uta
    Tichy, Diana
    Besemer, Britta
    Duerig, Jan
    Schroers, Roland
    Metzler, Ivana V.
    Haenel, Mathias
    Mann, Christoph
    Asemissen, Anne-Marie
    Heilmeier, Bernhard
    Huhn, Stefanie
    Kriegsmann, Katharina
    Weinhold, Niels
    Luntz, Steffen P.
    Holderried, Tobias A. W.
    Trautmann-Grill, Karolin
    Gezer, Deniz
    Klaiber-Hakimi, Maika
    Mueller, Martin
    Khandanpour, Cyrus
    Knauf, Wolfgang
    Munder, Markus
    Geer, Thomas
    Riesenberg, Hendrik
    Thomalla, Joerg
    Hoffmann, Martin
    Raab, Marc-Steffen
    Salwender, Hans
    Weisel, Katja
    BLOOD, 2021, 138
  • [7] A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)
    Berdeja, Jesus G.
    Gregory, Tara K.
    Kambhampati, Suman
    Anz, Bertrand M., III
    Tarantolo, Stefano R.
    Meluch, Anthony A.
    Matous, Jeffrey V.
    BLOOD, 2019, 134
  • [8] Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
    Kohmei Kubo
    Mitsuo Hori
    Kensuke Ohta
    Hiroshi Handa
    Kiyohiko Hatake
    Morio Matsumoto
    Shotaro Hagiwara
    Kazuteru Ohashi
    Chiaki Nakaseko
    Kenshi Suzuki
    Shigeki Ito
    Gen Kinoshita
    Suresh G. Shelat
    Masafumi Miyoshi
    Naoki Takezako
    International Journal of Hematology, 2020, 111 : 65 - 74
  • [9] Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
    Kubo, Kohmei
    Hori, Mitsuo
    Ohta, Kensuke
    Handa, Hiroshi
    Hatake, Kiyohiko
    Matsumoto, Morio
    Hagiwara, Shotaro
    Ohashi, Kazuteru
    Nakaseko, Chiaki
    Suzuki, Kenshi
    Ito, Shigeki
    Kinoshita, Gen
    Shelat, Suresh G.
    Miyoshi, Masafumi
    Takezako, Naoki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (01) : 65 - 74
  • [10] Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial
    O'Donnell, Elizabeth
    Mo, Clifton
    Yee, Andrew J.
    Nadeem, Omar
    Laubach, Jacob
    Rosenblatt, Jacalyn
    Munshi, Nikhil
    Midha, Shonali
    Cirstea, Diana
    Chrysafi, Pavlina
    Horick, Nora
    Richardson, Paul G.
    Raje, Noopur
    LANCET HAEMATOLOGY, 2024, 11 (06): : e415 - e424
12345